Hikal Limited has filed a comprehensive disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015 regarding the conversion of its promoter group entity Castilia Life Sciences Private Limited into a Limited Liability Partnership structure. The company submitted the disclosure on 18th February 2026 following the Ministry of Corporate Affairs approval and Certificate of Registration dated 17th February 2026.

SEBI PIT Regulations Compliance

The disclosure was made pursuant to Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Hikal submitted Form C disclosures to both BSE Limited (Scrip Code: 524735) and National Stock Exchange of India Limited (Symbol: HIKAL) detailing the transfer of equity shares resulting from the corporate conversion.

Corporate Conversion Details

The Ministry of Corporate Affairs approved the conversion on 17th February 2026, facilitating the transfer of all assets, rights, liabilities and interests to Castilia Life Sciences LLP. The conversion resulted in 3,02,31,914 shares of Hikal Limited, representing 24.52% of the company's total voting capital, being vested in the newly formed LLP structure.

Form C Disclosure Requirements

Castilia Life Sciences LLP submitted the mandatory Form C disclosure under Regulation 7(2) read with Regulation 6(2) for continual disclosure requirements. The form detailed the acquisition of shares through corporate conversion rather than market transactions, with the designated partner Sugandha Hiremath signing the disclosure documentation.

Regulatory Documentation

The comprehensive filing includes formal communications from both Hikal Limited and Castilia Life Sciences LLP confirming the share transfer mechanism. Company Secretary Rajasekhar Reddy digitally signed the disclosure at 17:00:10 on 18th February 2026, ensuring complete regulatory compliance under the SEBI framework.

The transaction represents a strategic corporate restructuring maintaining promoter group shareholding while transitioning to an optimized Limited Liability Partnership structure approved by the Ministry of Corporate Affairs.

Hikal Limited has reported its financial results for the quarter and nine months ended December 31, 2025, demonstrating a clear return to operational profitability. The pharmaceutical and specialty chemicals company held its earnings conference call on February 11, 2026, providing comprehensive insights into its performance and strategic direction.

Financial Performance Overview

The company's consolidated performance for the reporting period reflects steady recovery across business segments:

The finance cost for Q3 FY26 decreased by 17% year-on-year due to lower debt levels and reduced interest rates. The company maintained its debt-equity ratio at 0.58 as of December 31, 2025.

Dividend Declaration and Corporate Actions

Hikal's Board of Directors approved an interim dividend of ₹0.2 per share (10% of face value) at their meeting on February 11, 2026. The company has set February 17, 2026 as the record date for determining shareholder eligibility for the interim dividend payment for FY 2025-26.

Pharmaceutical Segment Recovery

The Pharmaceutical division showed significant improvement with revenue of ₹337 crores and EBIT margin of 12.3% for Q3 FY26. The segment has successfully navigated regulatory challenges, with remediation measures substantially implemented following the U.S. FDA audit.

Key developments in the pharmaceutical business include:

• Supply resumptions progressing as per internal forecasts
• Strengthened quality management systems and processes
• Robust pipeline of niche molecules in oncology, CNS, and gastroenterology
• New high-potency laboratory and R&D centre operational in Pune
• Dual-site validation mandate for critical APIs to mitigate supply chain risks

Crop Protection and Diversification Strategy

The Crop Protection segment recorded revenue of ₹157 crores with an EBIT margin of 3% during the quarter. While facing persistent pricing pressures and structural overcapacity, the company is accelerating its portfolio diversification into specialty chemicals, particularly the Personal Care segment.

Strategic Investments and Future Outlook

Hikal has invested ₹100 crores in capital expenditure during the nine-month period, focusing on debottlenecking, regulatory upgrades, and expanding CDMO capacities. The company expects meaningful revenue from the Personal Care segment to commence in the next fiscal year.

The Animal Health business continues to gain traction with sustained momentum in outsourcing activities. The company maintains a master plan to build this into a ₹500 crores plus business over the next 4-5 years.

Management expressed confidence that the worst challenges of the past three years are behind them, with strengthened operations, enhanced quality systems, and diversified business segments positioning the company for sustainable growth in FY27 and beyond.

Source: Hikal Limited earnings call transcript